Foresite Capital Management VI LLC
CIK: 2013341
Holdings (23)
Q2 2026 13F, quarter ended Jun 30, 2026, filed Aug 14, 2026
- CGON
CG Oncology, Inc.
$168.36M
2.37M sh26.20%+6.7% - ALMS
ALUMIS INC.
$119.53M
4.25M sh18.60%+0.0% - SPTX
Seaport Therapeutics, Inc.
$38.65M
1.78M sh6.02%New - DNLI
Denali Therapeutics Inc.
$35.92M
1.40M sh5.59%+15.4% - CLDX
Celldex Therapeutics, Inc.
$32.73M
879,713 sh5.09%+178.5% - AGIO
AGIOS PHARMACEUTICALS, INC.
$29.13M
785,000 sh4.53%+49.5% - CRVS
Corvus Pharmaceuticals, Inc.
$27.36M
1.83M sh4.26%+0.0% - PBLS
Parabilis Medicines, Inc.
$27.34M
999,044 sh4.26%New - GHRS
GH Research PLC
$25.28M
940,493 sh3.93%+198.1% - JBIO
Jade Biosciences, Inc.
$19.7M
886,667 sh3.07%+177.1% - HNGE
Hinge Health, Inc.
$18.29M
220,400 sh2.85%+0.0% - KYMR
Kymera Therapeutics, Inc.
$16.78M
146,332 sh2.61%+0.0% - ATAI
AtaiBeckley Inc.
$14.49M
2.75M sh2.26%+0.0% - VSTM
Verastem, Inc.
$12.02M
3.15M sh1.87%+0.0% - BEAM
Beam Therapeutics Inc.
$11.33M
330,000 sh1.76%New - NERV
Minerva Neurosciences, Inc.
$11.02M
1.99M sh1.71%-0.1% - AVBP
ArriVent BioPharma, Inc.
$10.47M
301,341 sh1.63%New - AURA
Aura Biosciences, Inc.
$9.47M
1.33M sh1.47%New - CRNX
Crinetics Pharmaceuticals, Inc.
$7.93M
212,010 sh1.23%+0.0% - RACC
Research Alliance Corp III
$3.21M
300,000 sh0.50%New - ZURA
Zura Bio Ltd
$2.65M
450,000 sh0.41%+0.0% - KLRA
Kailera Therapeutics, Inc.
$826K
37,500 sh0.13%New - IRON
Disc Medicine, Inc.
$71K
970 sh0.01%New
| Security | Shares | Value | Change | Weight | Period |
|---|---|---|---|---|---|
 CGON CG Oncology, Inc. | 2.37M | $168.36M | +6.7% | 26.20% | Q2 2026 |
 ALMS ALUMIS INC. | 4.25M | $119.53M | +0.0% | 18.60% | Q2 2026 |
 SPTX Seaport Therapeutics, Inc. | 1.78M | $38.65M | New | 6.02% | Q2 2026 |
 DNLI Denali Therapeutics Inc. | 1.40M | $35.92M | +15.4% | 5.59% | Q2 2026 |
 CLDX Celldex Therapeutics, Inc. | 879,713 | $32.73M | +178.5% | 5.09% | Q2 2026 |
 AGIO AGIOS PHARMACEUTICALS, INC. | 785,000 | $29.13M | +49.5% | 4.53% | Q2 2026 |
 CRVS Corvus Pharmaceuticals, Inc. | 1.83M | $27.36M | +0.0% | 4.26% | Q2 2026 |
 PBLS Parabilis Medicines, Inc. | 999,044 | $27.34M | New | 4.26% | Q2 2026 |
 GHRS GH Research PLC | 940,493 | $25.28M | +198.1% | 3.93% | Q2 2026 |
 JBIO Jade Biosciences, Inc. | 886,667 | $19.7M | +177.1% | 3.07% | Q2 2026 |
 HNGE Hinge Health, Inc. | 220,400 | $18.29M | +0.0% | 2.85% | Q2 2026 |
 KYMR Kymera Therapeutics, Inc. | 146,332 | $16.78M | +0.0% | 2.61% | Q2 2026 |
 ATAI AtaiBeckley Inc. | 2.75M | $14.49M | +0.0% | 2.26% | Q2 2026 |
 VSTM Verastem, Inc. | 3.15M | $12.02M | +0.0% | 1.87% | Q2 2026 |
 BEAM Beam Therapeutics Inc. | 330,000 | $11.33M | New | 1.76% | Q2 2026 |
 NERV Minerva Neurosciences, Inc. | 1.99M | $11.02M | -0.1% | 1.71% | Q2 2026 |
 AVBP ArriVent BioPharma, Inc. | 301,341 | $10.47M | New | 1.63% | Q2 2026 |
 AURA Aura Biosciences, Inc. | 1.33M | $9.47M | New | 1.47% | Q2 2026 |
 CRNX Crinetics Pharmaceuticals, Inc. | 212,010 | $7.93M | +0.0% | 1.23% | Q2 2026 |
 RACC Research Alliance Corp III | 300,000 | $3.21M | New | 0.50% | Q2 2026 |
 ZURA Zura Bio Ltd | 450,000 | $2.65M | +0.0% | 0.41% | Q2 2026 |
 KLRA Kailera Therapeutics, Inc. | 37,500 | $826K | New | 0.13% | Q2 2026 |
 IRON Disc Medicine, Inc. | 970 | $71K | New | 0.01% | Q2 2026 |
1-23 of 23 holdings
Sector Allocation
SEC Filings
| Form | Description | Filed |
|---|---|---|
About Foresite Capital Management VI LLC
Foresite Capital Management VI LLC is an Investment Adviser that reports its US-listed stock and option positions to the SEC on Form 13F (CIK 2013341). Signal8 holds 13 13F filings from it. Its SEC filings list Delaware as its state of incorporation.
Its most recent 13F holdings report covers Q2 2026 (the quarter ended Jun 30, 2026) and was filed on Aug 14, 2026. That report lists 23 securities, not counting options, up from 17 in Q1 2026.
Its five largest reported positions, in order, are CG Oncology, Inc. (CGON), ALUMIS INC. (ALMS), Seaport Therapeutics, Inc. (SPTX), Denali Therapeutics Inc. (DNLI) and Celldex Therapeutics, Inc. (CLDX). The next five are AGIOS PHARMACEUTICALS, INC. (AGIO), Corvus Pharmaceuticals, Inc. (CRVS), Parabilis Medicines, Inc. (PBLS), GH Research PLC (GHRS) and Jade Biosciences, Inc. (JBIO).
Recent 13F filings by Foresite Capital Management VI LLC
- Q2 2026: 13F-HR filed Aug 14, 2026, listing 23 securities.
- Q1 2026: 13F-HR filed May 15, 2026, listing 17 securities.
- Q4 2025: 13F-HR filed Feb 13, 2026, listing 12 securities.
- Q3 2025: 13F-HR filed Nov 14, 2025, listing 12 securities.
- Q2 2025: 13F-HR filed Aug 12, 2025, listing 20 securities.
- Q1 2025: 13F-HR filed May 15, 2025, listing 14 securities.